Siddhi A. Darji
Research Subjects
Siddhi A. Darji has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Devjani Banerjee
GSFC University
6 shared publications - Rupal Patel
Pramukhswami Medical College, Bhaikaka University, Karamsad Medical College, Anand, India
3 shared publications - Avani Raulji2 shared publications
- Chirag Patel
Department of Microbiology, Pramukhswami Medical College, Bhaikaka University, Karamsad, India
2 shared publications - Himanshu Pandya
Professor, Department of Medicine, Pramukhswami Medical College, Karamsad, Anand, Gujarat, India
2 shared publications - Jainikkumar Patel2 shared publications
Latest Publications
- Open Access
- 2 August 2026
- Published by Elsevier in SSRN Electronic Journal
Diagnostic Accuracy of the Resist-5 O.K.N.V.I. Immunochromatographic Assay for Detection of Carbapenemase-Producing Gram-Negative Bacteria: Comparison with Real-Time PCR
Gram-negative bacteria resistant to carbapenems have now become a major global health threat due to limited therapeutic options and high mortality. Rapid and meticulous detection of carbapenemase genes is crucial for targeted antimicrobial treatment and infection control. This study evaluated the diagnostic performance of the Resist-5 O.K.N.V.I. immunochromatographic test (ICT) compared with Real-time polymerase chain reaction (RT-PCR) to detect major carbapenemase genes. A prospective diagnostic accuracy study included 252 clinical isolates of Gram-negative bacteria resistant to carbapenem. The ICT assay was evaluated for detection of five major carbapenemase genes (blaNDM, blaKPC, blaVIM, blaIMP, blaOXA-48), using RT-PCR as the reference standard. Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) were calculated. The Gene-level ICT assay showed a sensitivity of 99.66% and a specificity of 99.90%, with a PPV of 99.66%, and an NPV of 99.90%. Overall agreement between ICT and RT-PCR was excellent (Cohen’s kappa = 0.996). The Resist-5 O.K.N.V.I. ICT assay is a quick, reliable, and economical detection device for screening of major carbapenemase genes. Nevertheless, molecular tests are still necessary for confirmatory testing.
- 2 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDiagnostic Accuracy of the Resist-5 O.K.N.V.I. Immunochromatographic Assay for Detection of Carbapenemase-Producing Gram-Negative Bacteria: Comparison with Real-Time PCR
Gram-negative bacteria resistant to carbapenems have now become a major global health threat due to limited therapeutic options and high mortality. Rapid and meticulous detection of carbapenemase genes is crucial for targeted antimicrobial treatment and infection control. This study evaluated the diagnostic performance of the Resist-5 O.K.N.V.I. immunochromatographic test (ICT) compared with Real-time polymerase chain reaction (RT-PCR) to detect major carbapenemase genes. A prospective diagnostic accuracy study included 252 clinical isolates of Gram-negative bacteria resistant to carbapenem. The ICT assay was evaluated for detection of five major carbapenemase genes (blaNDM, blaKPC, blaVIM, blaIMP, blaOXA-48), using RT-PCR as the reference standard. Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) were calculated. The Gene-level ICT assay showed a sensitivity of 99.66% and a specificity of 99.90%, with a PPV of 99.66%, and an NPV of 99.90%. Overall agreement between ICT and RT-PCR was excellent (Cohen’s kappa = 0.996). The Resist-5 O.K.N.V.I. ICT assay is a quick, reliable, and economical detection device for screening of major carbapenemase genes. Nevertheless, molecular tests are still necessary for confirmatory testing.
- 17 February 2026
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 79 (4) , 264-273
Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli
Antimicrobial resistance (AMR) in Escherichia coli (E.coli) poses a significant global threat to public health due to increasing resistance against antibiotics. This study explored a novel combination therapy by investigating the synergistic potential of three distinct antibiotics to combat AMR in E. coli isolates. Multi drug resistant (MDR), extensive drug resistant (XDR), and pan drug resistant (PDR) E. coli isolates were confirmed using the automated system Vitek followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Dual and triple combinations of meropenem, ceftazidime, and polymyxin B were evaluated using a checkerboard assay and were further corroborated using field emission scanning electron microscopy (FE-SEM). Checkerboard assays demonstrated significant bactericidal activity up to 24 h for all MDR, XDR, and PDR isolates treated with combinations of meropenem + polymyxin B; ceftazidime + polymyxin B and meropenem + ceftazidime + polymyxin B. Notably, few of the XDR and PDR isolates showed no bacterial growth for up to 96 h with meropenem + polymyxin B; ceftazidime + polymyxin B; and meropenem + ceftazidime + polymyxin B combinations. FE-SEM images supported these findings, revealing significant plasmolysis with meropenem + polymyxin B; ceftazidime + polymyxin B; and meropenem + ceftazidime + polymyxin B treatments compared to the control. Dual and triple combination regimens were found to be effective for treating MDR, XDR, and PDR isolates. The present study suggested a promising strategy in in vitro conditions, but its effectiveness still requires further in vivo validation considering pharmacokinetics/pharmacodynamics (PK-PD) modeling and dynamic dosing regimens.
- 17 February 2026
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 79 (4) , 264-273
Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli
Antimicrobial resistance (AMR) in Escherichia coli (E.coli) poses a significant global threat to public health due to increasing resistance against antibiotics. This study explored a novel combination therapy by investigating the synergistic potential of three distinct antibiotics to combat AMR in E. coli isolates. Multi drug resistant (MDR), extensive drug resistant (XDR), and pan drug resistant (PDR) E. coli isolates were confirmed using the automated system Vitek followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Dual and triple combinations of meropenem, ceftazidime, and polymyxin B were evaluated using a checkerboard assay and were further corroborated using field emission scanning electron microscopy (FE-SEM). Checkerboard assays demonstrated significant bactericidal activity up to 24 h for all MDR, XDR, and PDR isolates treated with combinations of meropenem + polymyxin B; ceftazidime + polymyxin B and meropenem + ceftazidime + polymyxin B. Notably, few of the XDR and PDR isolates showed no bacterial growth for up to 96 h with meropenem + polymyxin B; ceftazidime + polymyxin B; and meropenem + ceftazidime + polymyxin B combinations. FE-SEM images supported these findings, revealing significant plasmolysis with meropenem + polymyxin B; ceftazidime + polymyxin B; and meropenem + ceftazidime + polymyxin B treatments compared to the control. Dual and triple combination regimens were found to be effective for treating MDR, XDR, and PDR isolates. The present study suggested a promising strategy in in vitro conditions, but its effectiveness still requires further in vivo validation considering pharmacokinetics/pharmacodynamics (PK-PD) modeling and dynamic dosing regimens.
- 23 September 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 58, 100980
Co-occurrence of novel TEM-264 and NDM-88 in Escherichia coli isolated from urine sample of 72-year-Old female patient, Gujarat, India
- 23 September 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 58, 100980
Co-occurrence of novel TEM-264 and NDM-88 in Escherichia coli isolated from urine sample of 72-year-Old female patient, Gujarat, India
- 8 December 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (3) , 1116-1128
Mutations in V84I & A184V of bla TEM cluster plays a pivotal role in the dynamics of Ω-loop leading to genesis of IR-TEM
The Enterobacteriaceae family exhibits resistance to antibiotics by producing β-Lactamase. Mutations in β-Lactamase, have led to the generation of inhibitor resistant variants known as IR-TEM. In the present study, IR-TEM β-Lactamase of Enterobacter hormaechei and Enterobacter asburiae was compared. To investigate the mechanism behind the conferred mutation, we studied its interaction with Clavulanic acid, (β-Lactamase inhibitor) with different lineages of TEM and IR-TEM. We found that Clavulanic acid quickly left the binding pockets of both variants using molecular dynamics (MD) simulations. Interestingly, mutations at the V84I and A184V positions were found to drastically influence the protein dynamics. Mutating the residues at V84I and A184V positions by computational mutagenesis in Enterobacter hormaechei, it was observed that the residues on the Ω-loop as well as a few downstream residues were primarily involved in generating resistance towards inhibitors by conferring increased flexibility to the loop. This further strongly supports the notion that inhibitor resistance in β-Lactamase is conferred through allosteric regulation, wherein mutations in positions 84 and 184 may play an important role in regulating the movement of the Ω-loop. These two positions determine the lineage pattern between two clusters in TEM-1 and TEM-116. To date, no reports have been made regarding the importance of these mutations and their dynamics in Ω-loop.Communicated by Ramaswamy H. Sarma.
- 8 December 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (3) , 1116-1128
Mutations in V84I & A184V of bla TEM cluster plays a pivotal role in the dynamics of Ω-loop leading to genesis of IR-TEM
The Enterobacteriaceae family exhibits resistance to antibiotics by producing β-Lactamase. Mutations in β-Lactamase, have led to the generation of inhibitor resistant variants known as IR-TEM. In the present study, IR-TEM β-Lactamase of Enterobacter hormaechei and Enterobacter asburiae was compared. To investigate the mechanism behind the conferred mutation, we studied its interaction with Clavulanic acid, (β-Lactamase inhibitor) with different lineages of TEM and IR-TEM. We found that Clavulanic acid quickly left the binding pockets of both variants using molecular dynamics (MD) simulations. Interestingly, mutations at the V84I and A184V positions were found to drastically influence the protein dynamics. Mutating the residues at V84I and A184V positions by computational mutagenesis in Enterobacter hormaechei, it was observed that the residues on the Ω-loop as well as a few downstream residues were primarily involved in generating resistance towards inhibitors by conferring increased flexibility to the loop. This further strongly supports the notion that inhibitor resistance in β-Lactamase is conferred through allosteric regulation, wherein mutations in positions 84 and 184 may play an important role in regulating the movement of the Ω-loop. These two positions determine the lineage pattern between two clusters in TEM-1 and TEM-116. To date, no reports have been made regarding the importance of these mutations and their dynamics in Ω-loop.Communicated by Ramaswamy H. Sarma.
- 1 January 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 890, 173720
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19
- 1 January 2021
- Published by Elsevier in European Journal of Pharmacology
- Vol. 890, 173720
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19